Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

ESC Congress 2004: Dronedarone is effective and well-tolerated in the prevention of atrial fibrillation recurrence

30.08.2004


On behalf of the Steering Committee of the American-Australian-African trial with DronedarONe In atrial fibrillation or flutter patients for the maintenance of Sinus rhythm



ADONIS trial findings presented at the European Society of Cardiology Congress in Munich

The findings of the “American-Australian-African trial with DronedarONe In atrial fibrillation or flutter patients for the maintenance of Sinus rhythm” (ADONIS) trial, announced today at the annual meeting of the European Society of Cardiology in Munich, Germany showed that the new anti-arrhythmic agent, dronedarone, is highly effective in the prevention of atrial fibrillation or atrial flutter recurrence, serious disorders of cardiac rhythm, and is well-tolerated by patients. ADONIS is part of the clinical investigation program on the novel multi-channel blocker, dronedarone, in this patient population, which also includes the European trial EURIDIS (EURopean trial In atrial fibrillation or flutter patients receiving Dronedarone for the maIntenance of Sinus rhythm).


The ADONIS trial involved 625 patients in 115 centers in the US, Canada, Argentina, Australia and South Africa. The study compared the efficacy and safety of dronedarone to placebo in patients who had already had at least one ECG-documented atrial fibrillation or flutter in the three month period prior to randomization and who were in sinus rhythm for at least one hour at the time of randomization. Using 2:1 randomization in order to optimize the assessment of safety parameters, patients received either 400 mg bid of dronedarone (n=417)or placebo (n=208) for a period of 12 months. The primary endpoint of ADONIS was the time from randomization to the first adjudicated recurrence of atrial fibrillation or flutter (AF/AFL) within the 12 month study period. All recurrences of AF/AFL had to last for at least ten minutes and were confirmed by two consecutive electrocardiograms (ECGs) or Trans-Telephonic Electrocardiographic Monitoring (TTEM) tracings recorded approximately 10 minutes apart and both showing atrial fibrillation or flutter.

“ADONIS demonstrated that dronedarone is a highly effective and well tolerated agent in the prevention of both symptomatic and asymptomatic recurrences of AF/AFL,” said Bramah N. Singh, MD, PhD, Professor of Medicine, Department of Medicine, Cardiology Division, UCLA Medical School and Chairman of the ADONIS trial Steering Committee. “Dronedarone was also shown to be effective in decreasing the heart rate of patients with AF recurrences and the drug’s cardiac tolerability was good with no cases of torsades de pointes,” he added.

The ADONIS study showed that the median time from randomization to a first adjudicated AF/AFL recurrence was 2.7-fold longer in the dronedarone group than in the placebo group. Dronedarone significantly decreased the risk of a first recurrence of AF/AFL within the 12-month study period by 27.5% compared to placebo (log-rank test p=0.0017).

Most initial AF/AFL recurrences were symptomatic in both groups of patients. Overall incidence of adverse events was comparable in the two groups (73% in the placebo arm and 80% in the dronedarone group, (p = ns)) and dronedarone also displayed good cardiac tolerability, with no cases of torsades de pointes.

“The results of the ADONIS and EURIDIS trials show remarkable consistency for both the antiarrhythmic efficacy as well as the safety of dronedarone,” said Stefan Hohnloser MD, PhD, Professor of Medicine, Department of Internal Medicine J.W. Goethe University, Frankfurt, Germany and member of the EURIDIS trial Steering Committee. “Given the relatively poor benefit-to-risk ratios of currently available anti-arrhythmic therapies, the results of the EURIDIS and ADONIS trials appear to position dronedarone as a promising option for cardiac rhythm space and rate control in atrial fibrillation,” he added.

Camilla Dormer | alfa
Further information:
http://www.escardio.org

More articles from Health and Medicine:

nachricht Infants later diagnosed with autism follow adults’ gaze, but seldom initiate joint attention
24.05.2019 | Schwedischer Forschungsrat - The Swedish Research Council

nachricht When wheels and heads are spinning - DFG research project on motion sickness in automated driving
22.05.2019 | Technische Universität Berlin

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: New studies increase confidence in NASA's measure of Earth's temperature

A new assessment of NASA's record of global temperatures revealed that the agency's estimate of Earth's long-term temperature rise in recent decades is accurate to within less than a tenth of a degree Fahrenheit, providing confidence that past and future research is correctly capturing rising surface temperatures.

The most complete assessment ever of statistical uncertainty within the GISS Surface Temperature Analysis (GISTEMP) data product shows that the annual values...

Im Focus: The geometry of an electron determined for the first time

Physicists at the University of Basel are able to show for the first time how a single electron looks in an artificial atom. A newly developed method enables them to show the probability of an electron being present in a space. This allows improved control of electron spins, which could serve as the smallest information unit in a future quantum computer. The experiments were published in Physical Review Letters and the related theory in Physical Review B.

The spin of an electron is a promising candidate for use as the smallest information unit (qubit) of a quantum computer. Controlling and switching this spin or...

Im Focus: Self-repairing batteries

UTokyo engineers develop a way to create high-capacity long-life batteries

Engineers at the University of Tokyo continually pioneer new ways to improve battery technology. Professor Atsuo Yamada and his team recently developed a...

Im Focus: Quantum Cloud Computing with Self-Check

With a quantum coprocessor in the cloud, physicists from Innsbruck, Austria, open the door to the simulation of previously unsolvable problems in chemistry, materials research or high-energy physics. The research groups led by Rainer Blatt and Peter Zoller report in the journal Nature how they simulated particle physics phenomena on 20 quantum bits and how the quantum simulator self-verified the result for the first time.

Many scientists are currently working on investigating how quantum advantage can be exploited on hardware already available today. Three years ago, physicists...

Im Focus: Accelerating quantum technologies with materials processing at the atomic scale

'Quantum technologies' utilise the unique phenomena of quantum superposition and entanglement to encode and process information, with potentially profound benefits to a wide range of information technologies from communications to sensing and computing.

However a major challenge in developing these technologies is that the quantum phenomena are very fragile, and only a handful of physical systems have been...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

SEMANTiCS 2019 brings together industry leaders and data scientists in Karlsruhe

29.04.2019 | Event News

Revered mathematicians and computer scientists converge with 200 young researchers in Heidelberg!

17.04.2019 | Event News

First dust conference in the Central Asian part of the earth’s dust belt

15.04.2019 | Event News

 
Latest News

On Mars, sands shift to a different drum

24.05.2019 | Physics and Astronomy

Piedmont Atlanta first in Georgia to offer new minimally invasive treatment for emphysema

24.05.2019 | Medical Engineering

Chemical juggling with three particles

24.05.2019 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>